Greatly Transformed Sinovac Set to Reawaken on Wall Street?
Maker of the CoronaVac vaccine for Covid-19 could soon resume trading on the Nasdaq after a nearly three-year pause, following two key legal developments Key takeaways: Two key legal developments…
Recent Articles
RELATED ARTICLES
-
With healthier finances, Clover Bio shifts to flu and RSV vaccines
2197.HK
- Health Guard plans dual listing to fund HPV vaccine fight
- China’s mRNA pioneer Stemirna faces post-Covid reinvention test
-
Fosun Pharma, CanSino take different paths as Covid lift fade
2196.HK 6185.HK
-
Evergrande brings down the house on wild era for China property
3333.HK
- DDC Enterprise IPO fails to whet investor appetites on Wall Street
- Drink, snack or shares? Vending machine brand Quna seeks IPO cash
Discover hidden China stock gems in our weekly newsletter